FEB 23, 2021 8:00 AM PST

Dogs Versus AI-Powered Diagnostic Devices-Who Won?

WRITTEN BY: Tara Fernandez

We’ve heard of dogs sniffing out cancer—an unsurprising skill given that they have over 200 million scent receptors (40 times more than humans), each of which is 10,000 times more powerful than the ones in our noses. Dogs’ noses are so powerful that they can detect a single drop of liquid mixed in enough water to fill 20 Olympic-size swimming pools and trace amounts of cancer biomarkers in biological samples. A growing number of studies has demonstrated that trained dogs can detect cancers with remarkable accuracy: one study showing that dogs can pick out the urine samples from prostate cancer patients’ with 99 percent accuracy.

“Dogs, for now 15 years or so, have been shown to be the earliest, most accurate disease detectors for anything that we’ve ever tried,” said MIT researcher Andreas Mershin.

“So far, many different types of cancer have been detected earlier by dogs than any other technology.”

While many of us would welcome the idea of a canine presence at the doctor’s office, diagnostic dogs are unlikely to become standard features at healthcare institutions anytime soon. For one, researchers are still unsure of the specific biochemical compounds that dogs are detecting when they alert to the presence of disease. This makes the design of custom training regimens for specific conditions particularly challenging and difficult to test and control.

To overcome this, could next-generation sensors and AI-driven technologies capture dogs’ powerful diagnostic capabilities? Yes, says a team of MIT researchers led by Mershin who have built a miniaturized device that can detect and process chemical signals in a sample of air with sensitivities that surpass dogs’ abilities. By pairing this odor-detection system with machine-learning algorithms, the platform can analyze and identify the presence of “disease smells.” The study was published in PLOS One

Mershin and colleagues have been creating detector systems that use stabilized mammalian olfactory receptors as sensors, with the latest iteration being the product of many years of work. These in-built receptors can pick up volatile organic compounds and the presence of microbes in biological samples. No sophisticated computer systems are required to analyze the data collected—even a smartphone’s processing power could handle it. 

The team put their device to the test with 50 urine samples from healthy volunteers and patients with prostate cancer diagnoses. This side-by-side comparison using both the new platform and trained medical detection dogs brought surprising results: it was a tie. Both the canines and the artificial system red-flagged the cancer samples with over 70 percent accuracy.

The diagnostic device’s performance has significant room for improvement. After all, its sensors are around 200 times more sensitive than those in a dog’s nose. Tweaks and improvements to the algorithm could assist the system make sense of the complex odors it captures more effectively, linking them to the presence of disease.

“We knew that the sensors are already better than what the dogs can do in terms of the limit of detection, but what we haven’t shown before is that we can train an artificial intelligence to mimic the dogs,” said Mershin.

“And now we’ve shown that we can do this. We’ve shown that what the dog does can be replicated to a certain extent.”

This study points towards the potential and feasibility of an eventual clinical implementation of such a technology. Follow-up studies will expand the testing and validating scope, with Mershin hoping to study how the set-up performs in much larger panels of samples.

 

 

Sources: MIT News, PLOS One.


 

About the Author
  • Tara Fernandez has a PhD in Cell Biology and has spent over a decade uncovering the molecular basis of diseases ranging from skin cancer to obesity and diabetes. She currently works on developing and marketing disruptive new technologies in the biotechnology industry. Her areas of interest include innovation in molecular diagnostics, cell therapies, and immunology. She actively participates in various science communication and public engagement initiatives to promote STEM in the community.
You May Also Like
NOV 03, 2020
Clinical & Molecular DX
"Hello? It's Me, the Coronavirus."
NOV 03, 2020
"Hello? It's Me, the Coronavirus."
Researchers at MIT have discovered an unlikely way of discerning those with COVID-19 from healthy individuals — si ...
NOV 06, 2020
Clinical & Molecular DX
Your Earwax Says You're Depressed
NOV 06, 2020
Your Earwax Says You're Depressed
Cortisol, commonly known as the “stress hormone”, is the body’s built-in alarm system that sends siren ...
NOV 13, 2020
Chemistry & Physics
Mid-IR Spectroscopy a Convenient, Accurate Means of Cancer Diagnosis
NOV 13, 2020
Mid-IR Spectroscopy a Convenient, Accurate Means of Cancer Diagnosis
Last Sunday, November 8, was the International Day of Radiology (IDoR 2020), an event celebrated by radiologists, techno ...
JAN 26, 2021
Clinical & Molecular DX
Prostate Cancer Screening: No More False Positives
JAN 26, 2021
Prostate Cancer Screening: No More False Positives
A new diagnostic test powered by artificial intelligence has been found to detect prostate cancer markers in urine sampl ...
JAN 26, 2021
Cardiology
Your Nose Could Tell You Something About Your Heart Health
JAN 26, 2021
Your Nose Could Tell You Something About Your Heart Health
As we get older, many things change in our bodies. We lose touch with the newest fashion trends, or which new phone is b ...
FEB 11, 2021
Clinical & Molecular DX
Seeing if Hormone Therapy Will Work for Breast Cancer Patients
FEB 11, 2021
Seeing if Hormone Therapy Will Work for Breast Cancer Patients
Only around half of women diagnosed with breast cancer will benefit from hormonal therapy, a cancer treatment that adds, ...
Loading Comments...